Shield Therapeutics PLC (STX) Stock Rating Reaffirmed by Liberum Capital
Shield Therapeutics PLC (LON:STX)‘s stock had its “buy” rating reaffirmed by stock analysts at Liberum Capital in a research note issued to investors on Thursday. They currently have a GBX 245 ($3.16) price objective on the stock. Liberum Capital’s price target points to a potential upside of 55.56% from the company’s previous close.
STX has been the subject of several other reports. Peel Hunt reissued a “buy” rating and set a GBX 220 ($2.84) price objective on shares of Shield Therapeutics PLC in a research note on Thursday, July 6th. FinnCap started coverage on shares of Shield Therapeutics PLC in a research note on Thursday, September 7th. They set a “buy” rating and a GBX 270 ($3.49) price objective for the company.
Shares of Shield Therapeutics PLC (LON STX) opened at 157.50 on Thursday. The stock has a 50 day moving average price of GBX 157.50 and a 200 day moving average price of GBX 163.10. The firm’s market capitalization is GBX 170.10 million. Shield Therapeutics PLC has a 52 week low of GBX 152.25 and a 52 week high of GBX 177.00.
About Shield Therapeutics PLC
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.
Receive News & Stock Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related stocks with our FREE daily email newsletter.